The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-31 (IL-31) protein for the treatment and/or prevention of a pruritic condition and/or an allergic condition, such as atopic dermatitis. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.